Market Closed -
Nasdaq
04:30:00 2024-04-26 pm EDT
5-day change
1st Jan Change
2.21
USD
-3.28%
+1.84%
+3.76%
NEXGEL, Inc. Announces Partnership with STADA Arzneimittel AG to Distribute and Commercialize Consumer Health OTC Products in North America
December 11, 2023 at 08:00 am EST
NEXGEL, Inc. announced a partnership with STADA Arzneimittel AG to distribute and commercialize consumer health OTC products in North America in 2024.
NEXGEL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Apr. 01
CI
Transcript : NEXGEL, Inc., Q4 2023 Earnings Call, Apr 01, 2024
Apr. 01
Earnings Flash (NXGL) NEXGEL Posts Q4 Revenue $1.1M
Apr. 01
MT
NEXGEL, Inc. Provides Revenue Guidance for the First Quarter of 2023
Apr. 01
CI
NEXGEL, Inc. Announces Intention of Miranda J. Toledano to Resign as a Member of the Board of Directors, Effective as of March 31, 2024
Jan. 16
CI
Top Premarket Decliners
Jan. 16
MT
Nexgel Subsidiary, Cg Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024
Jan. 09
CI
NEXGEL, Inc. Announces Resignation of David Stefansky as Member of the Board of Directors
Dec. 12
CI
Nexgel Enters Deal With Stada Arzneimittel to Distribute OTC Products Across North America
Dec. 11
MT
NEXGEL, Inc. Announces Partnership with STADA Arzneimittel AG to Distribute and Commercialize Consumer Health OTC Products in North America
Dec. 11
CI
NEXGEL, Inc. acquired Kenkoderm from Olympus Trading Company, LLC for $1.1 million.
Dec. 04
CI
Tranche Update on NEXGEL, Inc.'s Equity Buyback Plan announced on December 7, 2022.
Nov. 13
CI
NEXGEL, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 13
CI
Transcript : NEXGEL, Inc., Q3 2023 Earnings Call, Nov 13, 2023
Nov. 13
Earnings Flash (NXGL) NEXGEL Reports Q3 Revenue $1.2M, vs. Street Est of $1.2M
Nov. 13
MT
Sector Update: Health Care Stocks Higher in Afternoon Trading
23-10-30
MT
NEXGEL Unit Executes Supply Agreement with AbbVie
23-10-30
MT
NEXGEL, Inc. Secures Supply Agreement with AbbVie Inc
23-10-30
CI
Tranche Update on NEXGEL, Inc.'s Equity Buyback Plan announced on December 7, 2022.
23-08-14
CI
NEXGEL, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-14
CI
Transcript : NEXGEL, Inc., Q2 2023 Earnings Call, Aug 14, 2023
23-08-14
Earnings Flash (NXGL) NEXGEL Reports Q2 Revenue $1.2M, vs. Street Est of $1M
23-08-14
MT
NEXGEL Partners With Enigma Health for Retail Distribution, Marketing Services in North America
23-07-19
MT
Transcript : NEXGEL, Inc., Q1 2023 Earnings Call, May 15, 2023
23-05-15
Tranche Update on NEXGEL, Inc.'s Equity Buyback Plan announced on December 7, 2022.
23-05-15
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
NexGel, Inc. is a provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its gels and its consumer products are manufactured using proprietary and non-proprietary mixing, coating, and crosslinking technologies. It markets under the brand names MedaGel and LumaGel Beauty. The products it sells under its MedaGel brand primarily relate to over the counter (OTC) remedy solutions, such as blister and pain applications; while the products it sells under its LumaGel Beauty brand primarily relate to beauty and cosmetic solutions, such as wrinkle and skin cream applications. The Company is also engaged in treating the symptoms of Psoriasis through its brand Kenkoderm.
More about the company
Last Close Price
2.21
USD
Average target price
6
USD
Spread / Average Target
+171.49%
Consensus
1st Jan change
Capi.
+3.76% 13.76M +25.83% 661B +27.00% 566B -6.76% 352B +20.34% 332B +3.00% 283B +13.09% 231B +5.46% 200B -9.61% 195B -6.26% 145B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
NEXGEL, INC. 
